CERo Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent Office Covering Company's Lead Compound CER-1236

BenzingaApr 10 08:16 ET

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for Its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

GlobeNewswireApr 9 08:15 ET

CERo Therapeutics Receives FDA Clearance For Second Investigational New Drug Application And Will Initiate Phase 1 Clinical Trial Of Lead Compound CER-1236 In Solid Tumors

BenzingaMar 31 08:18 ET

Express News | Cero Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

ReutersMar 31 08:15 ET

Express News | CERo Therapeutics Received Notice Of Allowance For US Patent Titled "CHIMERIC TIM4 RECEPTORS AND USES THEREOF (FOR THE TREATMENT OF CANCER)"

BenzingaMar 24 15:59 ET

CERo Therapeutics Partners With University Of California Davis For Manufacturing Of CER-1236 In Upcoming Phase 1 AML Trial; First Patient Dosing Anticipated H1 2025

BenzingaMar 19 08:16 ET